Idi na sadržaj

Idi na podizbornik

Jehovini svjedoci

hrvatski

Beta-talasemija (odrasli)

Beta-talasemija intermedija i minor – farmakološka indukcija sinteze fetalnog hemoglobina

Fetal hemoglobin inducers from the natural world: a novel approach for identification of drugs for the treatment of {beta}-thalassemia and sickle-cell anemia.

Bianchi N, Zuccato C, Lampronti I, Borgatti M, Gambari R.

Izvor‎: Evid Based Complement Alternat Med 2009;6(2):141-51.

Indeks‎: PubMed 18955291

DOI‎: 10.1093/ecam/nem139

http://www.ncbi.nlm.nih.gov/pubmed/18955291

Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from eastern India.

Bohara VV, Ray S, Chakrabarti P, Ray SS, Nath UK, Chaudhuri U.

Izvor‎: Hemoglobin. 2014;38(1):44-8.

Indeks‎: PubMed 24144212

DOI‎: 10.3109/03630269.2013.845844

http://www.ncbi.nlm.nih.gov/pubmed/24144212

Oral isobutyramide therapy in patients with thalassemia intermedia: results of a phase II open study.

Cappellini MD, Graziadei G, Ciceri L, Comino A, Bianchi P, Porcella A, Fiorelli G.

Izvor‎: Blood Cells Mol Dis 2000;26(1):105-11.

Indeks‎: PubMed 10772882

http://www.ncbi.nlm.nih.gov/pubmed/10772882

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules.

Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.

Izvor‎: Acta Haematol 2004;111(4):189-95.

Indeks‎: PubMed 15153710

http://www.ncbi.nlm.nih.gov/pubmed/15153710

Efficacy of erythropoietin on dialysis in patients with beta thalassemia minor.

Di Iorio B, De Nicola L, Bellizzi V, Minutolo R, Zamboli P, Rubino R, Fuiano G, Conte G.

Izvor‎: Blood Purif 2004;22(5):453-60.

Indeks‎: PubMed 15359104

http://www.ncbi.nlm.nih.gov/pubmed/15359104

Hydroxyurea in thalassemia intermedia--a promising therapy.

Dixit A, Chatterjee TC, Mishra P, Choudhry DR, Mahapatra M, Tyagi S, Kabra M, Saxena R, Choudhry VP.

Izvor‎: Ann Hematol 2005;84(7):441-6.

Indeks‎: PubMed 15838670

http://www.ncbi.nlm.nih.gov/pubmed/15838670

A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia.

Fucharoen S, Inati A, Siritanaratku N, Thein SL, Wargin WC, Koussa S, Taher A, Chaneim N, Boosalis M, Berenson R, Perrine SP.

Izvor‎: Br J Haematol 2013;161(4):587-93.

Indeks‎: PubMed 23530969

DOI‎: 10.1111/bjh.12304

http://www.ncbi.nlm.nih.gov/pubmed/23530969

Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study.

Italia KY, Jijina FF, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, Nair SB, Ghosh K, Colah RB.

Izvor‎: J Clin Pathol 2010;63(2):147-50.

Indeks‎: PubMed 20154037

DOI‎: 10.1136/jcp.2009.070391

http://www.ncbi.nlm.nih.gov/pubmed/20154037

Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia.

Karimi M, Borzouee M, Mehrabani A, Cohan N.

Izvor‎: Eur J Haematol 2009;82(3):213-8.

Indeks‎: PubMed 19077048

DOI‎: 10.1111/j.1600-0609.2008.01192.x

http://www.ncbi.nlm.nih.gov/pubmed/19077048

Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia.

Karimi M, Mohammadi F, Behmanesh F, Samani SM, Borzouee M, Amoozgar H, Haghpanah S.

Izvor‎: Eur J Haematol 2010;84(1):52-8.

Indeks‎: PubMed 19799627

DOI‎: 10.1111/j.1600-0609.2009.01356.x

http://www.ncbi.nlm.nih.gov/pubmed/19799627

Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.

Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.

Izvor‎: Blood Cells Mol Dis 2000;26(5):453-66.

Indeks‎: PubMed 11112383

http://www.ncbi.nlm.nih.gov/pubmed/11112383

The role of recombinant human erythropoietin in the treatment of thalassemia.

Rachmilewitz EA, Aker M.

Izvor‎: Ann N Y Acad Sci. 1998;850:129-38.

Indeks‎: PubMed 9668535

http://www.ncbi.nlm.nih.gov/pubmed/9668535

Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment.

Singer ST, Kuypers FA, Olivieri NF, Weatherall DJ, Mignacca R, Coates TD, Davies S, Sweeters N, Vichinsky EP.

Izvor‎: Ann N Y Acad Sci 2005;1054:250-6.

Indeks‎: PubMed 16339672

http://www.ncbi.nlm.nih.gov/pubmed/16339672

Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes.

Singer ST, Vichinsky EP, Sweeters N, Rachmilewitz E.

Izvor‎: Br J Haematol 2011;154(2):281-4.

Indeks‎: PubMed 21496003

DOI‎: 10.1111/j.1365-2141.2011.08617.x

http://www.ncbi.nlm.nih.gov/pubmed/21496003

Butyric acid: what is the future for this old substance?

Sossai P.

Izvor‎: Swiss Med Wkly 2012;142:w13596.

Indeks‎: PubMed 22674349

DOI‎: 10.4414/smw.2012.13596

http://www.ncbi.nlm.nih.gov/pubmed/22674349

The emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia.

Thein SL.

Izvor‎: Blood Rev 2012;26 Suppl 1:S35-9.

Indeks‎: PubMed 22631042

DOI‎: 10.1016/S0268-960X(12)70011-5

http://www.ncbi.nlm.nih.gov/pubmed/22631042


Medicinski sadržaji objavljeni na stranici jw.org namijenjeni su ponajprije liječnicima i drugim zdravstvenim radnicima. Ti sadržaji nisu medicinski savjeti ni preporuke za liječenje niti su zamjena za osposobljene zdravstvene radnike. Navedenu medicinsku literaturu nisu objavili Jehovini svjedoci. No ona može biti od pomoći liječnicima jer se u njoj razmatraju strategije alternativa transfuziji krvi. Svaki zdravstveni radnik dužan je biti u toku s najnovijim informacijama, upoznati se sa svim opcijama pružanja zdravstvene skrbi te pomoći pacijentima da donesu odluke u skladu sa svojim zdravstvenim stanjem, željama, nazorima i vjerovanjima. Nisu sve navedene strategije prihvatljive svim pacijentima niti se mogu primijeniti na sve njih.

Napomena pacijentima: Ako trebate savjet oko svog zdravstvenog stanja i liječenja, uvijek se obratite liječnicima ili drugim kvalificiranim zdravstvenim radnicima. Pomoć liječnika zatražite ako sumnjate da ste oboljeli.

Korištenje ove stranice podliježe uvjetima korištenja.